 Members | Associate Members | Membership | Committees | Symposium | Feature Article | Recent Publications | Seminars | Links |
| Welcome |
| Announcements/ News |
| Funding Opportunities |
| CTSA |
| Educational Programs |
| CTRC |
| Centers |
| Programs |
| Cores |
| Contact Us |
| Home |
| ITMAT Glossary |
 |
|
|
Tom Baillie, Ph.D. Vice President, Drug Metabolism | Merck Research Laboratories Thomas A. Baillie, Ph.D., D.Sc. is Vice President of Drug Metabolism at Merck Research Laboratories, West Point, PA. Prior to joining Merck in 1994, Dr. Baillie held successive faculty positions at the University of London, the University of California San Francisco and the University of Washington, and he was awarded a Senior International Fogarty Fellowship (1988-89). Dr. Baillie's research interests lie in the application of mass spectrometry and associated techniques to the study of xenobiotic metabolism and chemical toxicology. He is the author of some 250 publications, and serves on the advisory boards of several scientific journals and professional organizations. Susan M. Blaney, M.D. Professor of Pediatrics | Texas Children’s Cancer Center | Baylor College of Medicine Susan Blaney, M.D. is the Head of the Neuro-Oncology and Pharmacology Programs at Texas Children’s Cancer Center/Baylor College of Medicine. She is also the Associate Director of Clinical Research for the Dan L. Duncan Cancer Center and an Associate Director for the General Clinical Research Center at Baylor College of Medicine. Dr. Blaney serves as the Vice-Chair of Developmental Therapeutics for the Children’s Oncology Group Phase I and Pilot Consortium and is on the Steering Committee for the Pediatric Brain Tumor Consortium. Her expertise is in the development of new anti-cancer agents for children with recurrent or refractory malignancies, with a special emphasis on central nervous system tumors. Tom Caskey, M.D., F.A.C.P. Managing Director | Cogene Ventures C. Thomas Caskey advises on biotechnology and biomedical projects. Dr. Caskey is Managing Director of Cogene Ventures. He served as Senior Vice President, Research at Merck Research Laboratories (West Point and IRBM - Rome) and is a former Trustee and President of the Merck Genome Research Institute. A member of the Institute of Medicine and the National Academy of Sciences, Dr. Caskey has been awarded numerous academic and industry-related honors for his work in human genetics. He earned his medical doctorate from Duke University and is board certified in internal medicine, human genetics and molecular genetics. Barry Coller, M.D. Professor | Physician-in-Chief, Vice President for Medical Affairs | The Rockefeller University Barry S. Coller, M.D., is Vice President for Medical Affairs at The Rockefeller University and physician-in-chief of its hospital. A renowned physician, researcher and medical educator, Dr. Coller is an expert on the basic molecular mechanisms involved in blood clotting and thrombosis. His research accomplishments include the development of a monoclonal antibody to platelets that was developed into the drug abciximab, which is used throughout the world to prevent and treat heart attacks in select patient populations. Rory Collins, F.R.C.P, Fmed.Sci Professor of Medicine and Epidemiology | University of Oxford | Principal Investigator and CEO | UK Biobank In 1985 Rory Collins became co-director, with Professor Sir Richard Peto, of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996 he was appointed British Heart Foundation Professor of Medicine and Epidemiology at Oxford. He became Principal Investigator and Chief Executive of the UK Biobank genetic-epidemiology study of 500,000 people in September 2005. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer. Shaun Coughlin, M.D., Ph.D. Director, Cardiovascular Research Institute (CVRI) | Professor of Medicine and Cellular and Molecular Pharmacology Department of Biopharmaceutical Sciences | University of California San Francisco Dr. Coughlin is Director of the Cardiovascular Research Institute, UCSF. Dr. Coughlin was a co-founder of COR Therapeutics. His research involves proteases and protease-activated receptors as applied to cardiovascular disease. Helen H. Hobbs, M.D. Investigator Howard Hughes Medical Institute | University of Texas Southwestern Medical Center Helen Hobbs is a Professor of Internal Medicine and Molecular Genetics at the UT Southwestern where she spearheads the Human Genetics Center and the Donald W. Reynolds Cardiovascular Clinical Research Center. In her work she has used human genetics to elucidate key pathways in cholesterol and lipoprotein trafficking. She has provided evidence that sequence variations with major effects collectively contribute significantly to common traits and diseases. She is a member of the Institute of Medicine, the American Academy of Arts and Sciences and the National Academy of Sciences. She received the Heinrich Wieland Prize for metabolism research and the American Heart Association Clinical Research Prize. David B. Searls, Ph.D. Senior Vice President, Informatics | GlaxoSmithKline Pharmaceuticals David B. Searls heads informatics at GSK, managing both bioinformatics and cheminformatics functions at major research centers in North Carolina, the Philadelphia area, and the UK. His office is in King of Prussia, PA. Prior to 1995 he was on the faculty of the University of Pennsylvania in the Departments of Genetics and Computer and Information Science. His research interests lie in the computational linguistics of biological macromolecules, data integration, systems biology, and the application of decision sciences to drug discovery. He has undergraduate degrees in both philosophy and life sciences from MIT, a Masters in computer science from Penn, and a PhD in biology from Johns Hopkins. Alan Shaw, Ph.D. President and Chief Executive Officer | VaxInnate Corporation Alan Shaw, PhD is President of VaxInnate, a biotechnology company developing novel vaccines. Prior to joining VaxInnate, Dr. Shaw led programs in malaria vaccines and cytokine inhibitors at Biogen SA, Geneva, Switzerland. In 1990, he joined Merck Research Laboratories where he led the Department of Virus & Cell Biology and played various roles in the development and licensure of vaccines for varicella, measles-mumps-rubella-varicella combinations, zoster, rotavirus and human papillomavirus/cervical cancer. | |
